{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:34:22Z","timestamp":1793266462771,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinically significant portal hypertension (CSPH) drives cirrhosis-related complications (i.e. hepatic decompensation). Impaired nitric oxide (NO) bioavailability promotes sinusoidal vasoconstriction, which is the initial pathomechanism of CSPH development. Activation of soluble guanylyl cyclase (sGC), a key downstream effector of NO, facilitates sinusoidal vasodilation, which in turn may improve CSPH. Two phase II studies are being conducted to assess the efficacy of the NO-independent sGC activator BI 685509 in patients with CSPH due to various cirrhosis aetiologies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The 1366.0021 trial (NCT05161481) is a randomised, placebo-controlled, exploratory study that will assess BI 685509 (moderate or high dose) for 24\u00a0weeks in patients with CSPH due to alcohol-related liver disease. The 1366.0029 trial (NCT05282121) is a randomised, open-label, parallel-group, exploratory study that will assess BI 685509 (high dose) alone in patients with hepatitis B or C virus infection or non-alcoholic steatohepatitis (NASH) and in combination with 10\u00a0mg empagliflozin in patients with NASH and type 2 diabetes mellitus for 8\u00a0weeks. The 1366.0021 trial will enrol 105 patients, and the 1366.0029 trial will enrol 80 patients. In both studies, the primary endpoint is the change from baseline in hepatic venous pressure gradient (HVPG) until the end of treatment (24 or 8\u00a0weeks, respectively). Secondary endpoints include the proportion of patients with an HVPG reduction of\u2009&gt;10% from baseline, the development of decompensation events and the change from baseline in HVPG after 8\u00a0weeks in the 1366.0021 trial. In addition, the trials will assess changes in liver and spleen stiffness by transient elastography, changes in hepatic and renal function and the tolerability of BI 685509.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>These trials will enable assessment of the short-term (8\u00a0weeks) and longer-term (24\u00a0weeks) safety of BI 685509, and the effect of sGC activation by BI 685509 on CSPH due to various cirrhosis aetiologies. The trials will use central readings of the diagnostic gold standard HVPG for the primary endpoint, and changes in established non-invasive biomarkers, such as liver and spleen stiffness. Ultimately, these trials will provide key information for developing future phase III trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>1366.0021: EudraCT no. 2021\u2013001285-38; ClinicalTrials.gov NCT05161481. Registered on 17 December 2021, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05161481\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05161481<\/jats:ext-link>.<\/jats:p>\n                <jats:p>1366.0029: EudraCT no. 2021\u2013005171-40; ClinicalTrials.gov NCT05282121. Registered on 16 March 2022, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05282121\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05282121<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07291-3","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:02:41Z","timestamp":1682323361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Berzigotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Ertle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Gashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros","family":"Swallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tomisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"7291_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5(3):245\u2013266.","DOI":"10.1016\/S2468-1253(19)30349-8"},{"key":"7291_CR2","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.lanepe.2021.100240","volume":"12","author":"W Gu","year":"2022","unstructured":"Gu W, Hortlik H, Erasmus HP, et al. Trends and the course of liver cirrhosis and its complications in Germany: nationwide population-based study (2005 to 2018). Lancet Reg Health Eur. 2022;12:100240.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"7291_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310\u201335.","journal-title":"Hepatology"},{"issue":"1","key":"7291_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D'Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217\u201331.","journal-title":"J Hepatol"},{"key":"7291_CR5","doi-asserted-by":"crossref","unstructured":"Reiberger T, Schwabl P, Trauner M, et al. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp 2020(160).","DOI":"10.3791\/58819"},{"issue":"3","key":"7291_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hep.21090","volume":"43","author":"A Blasco","year":"2006","unstructured":"Blasco A, Forns X, Carri\u00f3n JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43(3):492\u20139.","journal-title":"Hepatology"},{"issue":"21","key":"7291_CR7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMoa044456","volume":"353","author":"RJ Groszmann","year":"2005","unstructured":"Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353(21):2254\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"7291_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481\u20138.","journal-title":"Gastroenterology"},{"issue":"9","key":"7291_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/j.1478-3231.2012.02830.x","volume":"32","author":"A Zipprich","year":"2012","unstructured":"Zipprich A, Garcia-Tsao G, Rogowski S, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32(9):1407\u201314.","journal-title":"Liver Int"},{"issue":"3","key":"7291_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743\u201352.","journal-title":"J Hepatol"},{"key":"7291_CR11","doi-asserted-by":"crossref","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension: Report of the Baveno VII Consensus Workshop: personalized care in portal hypertension. J Hepatol 2021.","DOI":"10.1007\/978-3-031-08552-9"},{"issue":"10181","key":"7291_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva C, Albillos A, Genesc\u00e0 J, et al. \u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393(10181):1597\u2013608.","journal-title":"Lancet"},{"issue":"11","key":"7291_CR13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","volume":"62","author":"T Reiberger","year":"2013","unstructured":"Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62(11):1634\u201341.","journal-title":"Gut"},{"issue":"3","key":"7291_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/hep.30314","volume":"69","author":"JG Abraldes","year":"2019","unstructured":"Abraldes JG, Trebicka J, Chalasani N, et al. Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension. Hepatology. 2019;69(3):1287\u201399.","journal-title":"Hepatology"},{"issue":"1","key":"7291_CR15","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","volume":"2","author":"SG Rodrigues","year":"2020","unstructured":"Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep. 2020;2(1):100063.","journal-title":"JHEP Rep"},{"issue":"1","key":"7291_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.21945","volume":"47","author":"AV Longacre","year":"2008","unstructured":"Longacre AV, Imaeda A, Garcia-Tsao G, Fraenkel L. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage. Hepatology. 2008;47(1):169\u201376.","journal-title":"Hepatology"},{"issue":"2","key":"7291_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1053\/jhep.2002.31432","volume":"35","author":"R Wiest","year":"2002","unstructured":"Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35(2):478\u201391.","journal-title":"Hepatology"},{"key":"7291_CR18","doi-asserted-by":"crossref","unstructured":"Navasa M, Chesta J, Bosch J, Rod\u00e9s J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989;96(4):1110\u20131118.","DOI":"10.1016\/0016-5085(89)91630-2"},{"issue":"6","key":"7291_CR19","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1053\/jhep.2003.50211","volume":"37","author":"JC Garc\u00eda-Pag\u00e1n","year":"2003","unstructured":"Garc\u00eda-Pag\u00e1n JC, Morillas R, Ba\u00f1ares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology. 2003;37(6):1260\u20136.","journal-title":"Hepatology"},{"issue":"2","key":"7291_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/gastro\/gox011","volume":"5","author":"P Schwabl","year":"2017","unstructured":"Schwabl P, Laleman W. Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf). 2017;5(2):90\u2013103.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"5","key":"7291_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/cld.97","volume":"1","author":"D Tripathi","year":"2012","unstructured":"Tripathi D. Drugs used in therapy of portal hypertension. Clin Liver Dis (Hoboken). 2012;1(5):136\u20138.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"5","key":"7291_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1055\/s-0037-1613893","volume":"83","author":"G Dangas","year":"2000","unstructured":"Dangas G, Smith DA, Unger AH, et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost. 2000;83(5):688\u201392.","journal-title":"Thromb Haemost"},{"issue":"16","key":"7291_CR23","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1161\/01.CIR.0000033635.42612.88","volume":"106","author":"DJ Lefer","year":"2002","unstructured":"Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002;106(16):2041\u20132.","journal-title":"Circulation"},{"issue":"2","key":"7291_CR24","doi-asserted-by":"publisher","first-page":"H768","DOI":"10.1152\/ajpheart.00826.2001","volume":"283","author":"K Bates","year":"2002","unstructured":"Bates K, Ruggeroli CE, Goldman S, Gaballa MA. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol. 2002;283(2):H768\u201375.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"7291_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749\u201355.","journal-title":"Gastroenterology"},{"issue":"7","key":"7291_CR26","doi-asserted-by":"publisher","first-page":"e030038","DOI":"10.1136\/bmjopen-2019-030038","volume":"9","author":"S Wan","year":"2019","unstructured":"Wan S, Huang C, Zhu X. Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients. BMJ Open. 2019;9(7):e030038.","journal-title":"BMJ Open"},{"key":"7291_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","volume":"81","author":"ER Derbyshire","year":"2012","unstructured":"Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81:533\u201359.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"7291_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1006\/bbrc.1999.1444","volume":"263","author":"J Budworth","year":"1999","unstructured":"Budworth J, Meillerais S, Charles I, Powell K. Tissue distribution of the human soluble guanylate cyclases. Biochem Biophys Res Commun. 1999;263(3):696\u2013701.","journal-title":"Biochem Biophys Res Commun"},{"key":"7291_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/164_2018_197","volume":"264","author":"P Sandner","year":"2021","unstructured":"Sandner P, Zimmer DP, Milne GT, et al. Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol. 2021;264:355\u201394.","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"7291_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.44.5.749","volume":"44","author":"AI Sarela","year":"1999","unstructured":"Sarela AI, Mihaimeed FM, Batten JJ, et al. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut. 1999;44(5):749\u201353.","journal-title":"Gut"},{"key":"7291_CR31","doi-asserted-by":"crossref","unstructured":"Morales-Ruiz M, Rodr\u00edguez-Vita J, Ribera J, Jim\u00e9nez W. Pathophysiology of portal hypertension. In: Lanzer P, editor. PanVascular Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 3631\u20133665.","DOI":"10.1007\/978-3-642-37078-6_144"},{"issue":"1","key":"7291_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2005.10.004","volume":"44","author":"DA Langer","year":"2006","unstructured":"Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol. 2006;44(1):209\u201316.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"7291_CR33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","volume":"122","author":"P Sandner","year":"2017","unstructured":"Sandner P, Stasch JP. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Respir Med. 2017;122(Suppl 1):S1\u20139.","journal-title":"Respir Med"},{"issue":"10","key":"7291_CR34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/2050640620944140","volume":"8","author":"K Brusilovskaya","year":"2020","unstructured":"Brusilovskaya K, K\u00f6nigshofer P, Lampach D, et al. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United European Gastroenterol J. 2020;8(10):1174\u201385.","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"7291_CR35","doi-asserted-by":"publisher","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","volume":"8","author":"P Schwabl","year":"2018","unstructured":"Schwabl P, Brusilovskaya K, Supper P, et al. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci Rep. 2018;8(1):9372.","journal-title":"Sci Rep"},{"issue":"20","key":"7291_CR36","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263\u201373.","journal-title":"Circulation"},{"key":"7291_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","volume":"21","author":"JP Stasch","year":"2015","unstructured":"Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol. 2015;21:95\u2013104.","journal-title":"Curr Opin Pharmacol"},{"key":"7291_CR38","unstructured":"Lawitz E, Reiberger T, Schattenberg JM, et al. Poster #2092 Phase Ib study of the soluble guanylate cyclase activator BI 685509 in patients with mild and moderate hepatic impairment. Poster presentation at AASLD The Liver Meeting\u00ae 2021."},{"issue":"4","key":"7291_CR39","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65(4):692\u20139.","journal-title":"J Hepatol"},{"issue":"10","key":"7291_CR40","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cgh.2015.04.013","volume":"13","author":"S Lens","year":"2015","unstructured":"Lens S, Rinc\u00f3n D, Garc\u00eda-Retortillo M, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13(10):1846-1853.e1841.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"7291_CR41","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1002\/hep.32033","volume":"74","author":"W Bai","year":"2021","unstructured":"Bai W, Al-Karaghouli M, Stach J, et al. Test-retest reliability and consistency of HVPG and impact on trial design: A study in 289 patients from 20 randomized controlled trials. Hepatology. 2021;74(6):3301\u201315.","journal-title":"Hepatology"},{"issue":"4","key":"7291_CR42","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/jhep.2003.50133","volume":"37","author":"JG Abraldes","year":"2003","unstructured":"Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37(4):902\u20138.","journal-title":"Hepatology"},{"key":"7291_CR43","doi-asserted-by":"crossref","unstructured":"Paternostro R, Becker J, Hofer BS, et al. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis 2021.","DOI":"10.1016\/j.dld.2021.09.009"},{"issue":"2","key":"7291_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","volume":"18","author":"L Turco","year":"2020","unstructured":"Turco L, Villanueva C, La Mura V, et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: A meta-analysis. Clin Gastroenterol Hepatol. 2020;18(2):313-327.e316.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"7291_CR45","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.30885","volume":"71","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer M, Kozbial K, Schwabl P, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology. 2020;71(3):1023\u201336.","journal-title":"Hepatology"},{"issue":"9","key":"7291_CR46","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/liv.15013","volume":"41","author":"J Rivera-Esteban","year":"2021","unstructured":"Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E. Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. Liver Int. 2021;41(9):1999\u20132008.","journal-title":"Liver Int"},{"key":"7291_CR47","doi-asserted-by":"crossref","unstructured":"Reiberger T. The value of liver and spleen stiffness for evaluation of portal hypertension in compensated cirrhosis. Hepatol Commun 2021.","DOI":"10.1002\/hep4.1855"},{"issue":"3","key":"7291_CR48","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jhep.2013.10.027","volume":"60","author":"S Augustin","year":"2014","unstructured":"Augustin S, Mill\u00e1n L, Gonz\u00e1lez A, et al. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: a prospective study. J Hepatol. 2014;60(3):561\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"7291_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jhep.2011.07.005","volume":"56","author":"L Castera","year":"2012","unstructured":"Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012;56(3):696\u2013703.","journal-title":"J Hepatol"},{"issue":"6","key":"7291_CR50","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jhep.2014.02.024","volume":"60","author":"A Colecchia","year":"2014","unstructured":"Colecchia A, Colli A, Casazza G, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol. 2014;60(6):1158\u201364.","journal-title":"J Hepatol"},{"issue":"3","key":"7291_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clinre.2017.11.002","volume":"42","author":"J Song","year":"2018","unstructured":"Song J, Huang J, Huang H, et al. Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension: A meta-analysis. Clin Res Hepatol Gastroenterol. 2018;42(3):216\u201326.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"7291_CR52","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75(3):659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"issue":"3","key":"7291_CR53","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jhep.2018.10.018","volume":"70","author":"HY Kim","year":"2019","unstructured":"Kim HY, So YH, Kim W, et al. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol. 2019;70(3):412\u201322.","journal-title":"J Hepatol"},{"issue":"5","key":"7291_CR54","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s12072-020-10062-w","volume":"14","author":"G Marasco","year":"2020","unstructured":"Marasco G, Dajti E, Ravaioli F, et al. Spleen stiffness measurement for assessing the response to \u03b2-blockers therapy for high-risk esophageal varices patients. Hepatol Int. 2020;14(5):850\u20137.","journal-title":"Hepatol Int"},{"issue":"6","key":"7291_CR55","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00330-014-3140-y","volume":"24","author":"G Ferraioli","year":"2014","unstructured":"Ferraioli G, Tinelli C, Lissandrin R, et al. Ultrasound point shear wave elastography assessment of liver and spleen stiffness: effect of training on repeatability of measurements. Eur Radiol. 2014;24(6):1283\u20139.","journal-title":"Eur Radiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07291-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07291-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07291-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:07:25Z","timestamp":1686820045000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07291-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7291"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07291-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"10 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials will be initiated at the respective study sites only after all required legal documentation has been reviewed and obtained, and the study protocol has been reviewed and approved by the responsible IRB\/IEC at both central and local levels. The same applies for the implementation of changes introduced by amendments. Receipt of signed and dated informed consent represents inclusion criteria for the trial. A trial investigator or delegate will obtain informed, freely given, written consent from each subject via a consent form, after confirming that the subject understands the study design and the content of the form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"All authors consent to the publication of this article. The Boehringer Ingelheim transparency and publication policy can be found on the following web page: trials.boehringer-ingelheim.com. The consent documents are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"TR has received grant support from AbbVie, Boehringer Ingelheim, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD, MYR Pharmaceuticals, Philips Healthcare, Pliant and Siemens; speaking honoraria from AbbVie, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD and Roche; consulting or advisory board fees from AbbVie, Bayer, Boehringer Ingelheim, Gilead Sciences, Intercept Pharmaceuticals, MSD and Siemens; and travel support from AbbVie, Boehringer Ingelheim, Gilead Sciences and Roche. AB has been an advisory board member for Inventiva, Bracco, General Electrics, and Boehringer Ingelheim. JT has received speaking and\/or consulting fees from Versantis, Gore, Boehringer-Ingelheim, Alexion, Falk, Mallinckrodt, Grifols and CSL Behring and was supported by the German Research Foundation (DFG) project ID 403224013 \u2013 SFB 1382 (A09), by the German Federal Ministry of Education and Research (BMBF) for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research and the Arts (HMWK) for the ENABLE and ACLF-I cluster projects. The MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875) and IHMCSA (project ID 964590) projects have received funding from the European Union\u2019s Horizon 2020 research and innovation programme. JE, IG, RS and AT are employees of Boehringer Ingelheim. The manuscript reflects only the authors\u2019 views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"293"}}